{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:39:34Z","timestamp":1790127574890,"version":"4.0.1"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"10","funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["5I01 BX 003862-01A2"],"award-info":[{"award-number":["5I01 BX 003862-01A2"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH R01 CA227277-05"],"award-info":[{"award-number":["NIH R01 CA227277-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA283699-01"],"award-info":[{"award-number":["1R01CA283699-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["USAMRAA-HT9425-23-1-0761"],"award-info":[{"award-number":["USAMRAA-HT9425-23-1-0761"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Advanced urinary bladder cancer is characterized by rapid progression and development of therapy resistance. About 30% of the patients are diagnosed with high-grade tumors (grade &amp;gt; T2a). A typical nonsurgical treatment is systemic chemotherapy using cisplatin (C) and gemcitabine (G). However, treatment failure and subsequent disease progression are common in treated patients, and adjuvant therapies are not significantly effective. The therapeutic potential of a molecular hybrid of ursolic acid (UA), a pentacyclic-triterpene conjugated to N-methyl piperazine (UA4), was tested on both na\u00efve (WT) and gemcitabine-resistant (GemR) variants of two human invasive bladder cancer cell lines, 5637 and T24. UA4 killed 5637 (4 \u00b5mol\/L), T24 (4 \u00b5mol\/L) WT, and GemR cells in vitro at equal potency. Pretreatment with UA4 followed by G synergistically killed WT and GemR cells by &amp;gt;50% compared with G followed by UA4. Oral gavage of UA4 (100 mg\/kg) inhibited WT and GemR tumor growth in athymic mice. UA4 + G was more effective against GemR tumors than either drug alone. Studies revealed cytotoxic autophagy as a mechanism of UA4 cytotoxicity. UA4 induced moderate apoptosis in T24 but not in 5637 cells. Mitochondrial integrity and function were most affected by UA4 because of high levels of reactive oxygen species, disruption of mitochondrial membrane, and cell cycle arrest. These effects were enhanced in the UA4 + G combination. UA4 was well-tolerated in mice, and oral gavage led to a serum level &amp;gt;1 \u00b5mol\/L with no systemic toxicity. These results show the potential of UA4 as a nontoxic alternative treatment for high-grade bladder cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/1535-7163.mct-23-0806","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T11:09:36Z","timestamp":1717067376000},"page":"1389-1403","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting Chemoresistance in Advanced Bladder Cancers with a Novel Adjuvant Strategy"],"prefix":"10.1158","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9724-2791","authenticated-orcid":false,"given":"Juliette R.","family":"Seremak","sequence":"first","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-7192","authenticated-orcid":false,"given":"Kunj Bihari","family":"Gupta","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3961-7492","authenticated-orcid":false,"given":"Sunilkanth","family":"Bonigala","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia. 1"},{"name":"Department of Microbiology, Immunology, and Cell Biology, West Virginia University, Morgantown, West Virginia. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5140-4475","authenticated-orcid":false,"given":"Elise","family":"Liu","sequence":"additional","affiliation":[{"name":"Medical College of Georgia, Augusta University, Augusta, Georgia. 3"},{"name":"Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee. 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7147-0075","authenticated-orcid":false,"given":"Brendan","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and Anatomy, Augusta University, Augusta, Georgia. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7720-7048","authenticated-orcid":false,"given":"Wenbo","family":"Zhi","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5326-7364","authenticated-orcid":false,"given":"Riham M.","family":"Bokhtia","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy Zagazig University, Zagazig, Egypt. 6"},{"name":"Department of Chemistry and Biochemistry, Augusta University, Augusta, Georgia. 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3668-104X","authenticated-orcid":false,"given":"Siva S.","family":"Panda","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry, Augusta University, Augusta, Georgia. 7"},{"name":"Biochemistry and Molecular Biology, Augusta University, Augusta, Georgia. 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9909-6545","authenticated-orcid":false,"given":"Vinata B.","family":"Lokeshwar","sequence":"additional","affiliation":[{"name":"Biochemistry and Molecular Biology, Augusta University, Augusta, Georgia. 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1763-4718","authenticated-orcid":false,"given":"Bal L.","family":"Lokeshwar","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"2026050520321814400_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: A Cancer J Cli"},{"key":"2026050520321814400_bib2","volume-title":"Statement on American Cancer Society\u2019s estimated bladder cancer cases in 2023","author":"Bladder Cancer Advocacy Network","year":"2023"},{"key":"2026050520321814400_bib3","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.urolonc.2022.10.031","article-title":"25 years International Bladder Cancer Network (IBCN): the past, the present, and the future","volume":"41","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Urol Oncol"},{"key":"2026050520321814400_bib4","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/cancers15030566","article-title":"Current and future landscape of perioperative treatment for muscle-invasive bladder cancer","volume":"15","author":"Esteban-Villarrubia","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026050520321814400_bib5","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-022-01802-3","article-title":"Therapeutic landscape beyond immunotherapy in advanced urothelial carcinoma: moving past the checkpoint","volume":"82","author":"Tripathi","year":"2022","journal-title":"Drugs"},{"key":"2026050520321814400_bib6","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.3390\/cancers14112578","article-title":"Molecular oncology of bladder cancer from inception to modern perspective","volume":"14","author":"Lokeshwar","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026050520321814400_bib7","doi-asserted-by":"crossref","first-page":"986359","DOI":"10.3389\/fimmu.2022.986359","article-title":"Neoadjuvant immunotherapy and chemoimmunotherapy for stage II-III muscle-invasive bladder cancer","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"2026050520321814400_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3831\/KPI.201.22.007","article-title":"Role of pentacyclic triterpenoids in chemoprevention and anticancer treatment: an overview on targets and underling mechanisms","volume":"22","author":"Ghante","year":"2019","journal-title":"J Pharmacopuncture"},{"key":"2026050520321814400_bib9","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.3390\/ijms21165920","article-title":"Ursolic acid-based derivatives as potential anticancer agents: an update","volume":"21","author":"Khwaza","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026050520321814400_bib10","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1021\/jf302529x","article-title":"Bioavailability, distribution, and antioxidative effects of selected triterpenes in mice","volume":"60","author":"Yin","year":"2012","journal-title":"J Agric Food Chem"},{"key":"2026050520321814400_bib11","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.3390\/molecules24152751","article-title":"Ursolic acid and its derivatives as bioactive agents","volume":"24","author":"Mlala","year":"2019","journal-title":"Molecules"},{"key":"2026050520321814400_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1158\/1535-7163.MCT-18-1167","article-title":"\u03b2-arrestins regulate stem cell-like phenotype and response to chemotherapy in bladder cancer","volume":"18","author":"Kallifatidis","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"2026050520321814400_bib13","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1158\/1078-0432.CCR-21-0422","article-title":"HYAL4-V1\/chondroitinase (chase) drives gemcitabine resistance and predicts chemotherapy failure in patients with bladder cancer","volume":"27","author":"Hasanali","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026050520321814400_bib14","doi-asserted-by":"crossref","first-page":"8265","DOI":"10.1158\/0008-5472.CAN-09-0374","article-title":"CXC receptor-1 silencing inhibits androgen-independent prostate cancer","volume":"69","author":"Shamaladevi","year":"2009","journal-title":"Cancer Res"},{"key":"2026050520321814400_bib15","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1038\/s41598-017-02918-3","article-title":"Inhibition of androgen receptor promotes CXC-chemokine receptor 7-mediated prostate cancer cell survival","volume":"7","author":"Hoy","year":"2017","journal-title":"Sci Rep"},{"key":"2026050520321814400_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ijc.10168","article-title":"Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model","volume":"98","author":"Lokeshwar","year":"2002","journal-title":"Int J Cancer"},{"key":"2026050520321814400_bib17","first-page":"361","article-title":"MitoSOX-based flow cytometry for detecting mitochondrial ROS","volume":"2","author":"Kauffman","year":"2016","journal-title":"React Oxyg Species (Apex)"},{"key":"2026050520321814400_bib18","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.1158\/1078-0432.CCR-04-1208","article-title":"Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs","volume":"10","author":"Dandekar","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2026050520321814400_bib19","doi-asserted-by":"crossref","first-page":"16379","DOI":"10.18632\/oncotarget.3834","article-title":"Polyphenol-rich extract of Pimenta dioica berries (Allspice) kills breast cancer cells by autophagy and delays growth of triple negative breast cancer in athymic mice","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"2026050520321814400_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00280-007-0625-2","article-title":"Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice","volume":"62","author":"Beumer","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026050520321814400_bib21","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.leu.2402114","article-title":"Nucleoside analogues: mechanisms of drug resistance and reversal strategies","volume":"15","author":"Galmarini","year":"2001","journal-title":"Leukemia"},{"key":"2026050520321814400_bib22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1593\/neo.10402","article-title":"MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy","volume":"12","author":"Hoffmann","year":"2010","journal-title":"Neoplasia"},{"key":"2026050520321814400_bib23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-94-017-7215-0_18","article-title":"Biomarker in cisplatin-based chemotherapy for urinary bladder cancer","volume":"867","author":"Ecke","year":"2015","journal-title":"Adv Exp Med Biol"},{"key":"2026050520321814400_bib24","first-page":"5000","article-title":"Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2\u2032,2\u2032-difluorodeoxycytidine- induced cytotoxicity","volume":"9","author":"Garcia-Manteiga","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2026050520321814400_bib25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1124\/dmd.119.089334","article-title":"Intracellular cytidine deaminase regulates gemcitabine metabolism in pancreatic cancer cell lines","volume":"48","author":"Bj\u00e5nes","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"2026050520321814400_bib26","first-page":"3047","article-title":"A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer","volume":"10","author":"Sohal","year":"2020","journal-title":"Am J Cancer Res"},{"key":"2026050520321814400_bib27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00280-010-1337-6","article-title":"Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice","volume":"67","author":"Beumer","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026050520321814400_bib28","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s43440-023-00512-1","article-title":"Anticancer effect of terpenes: focus on malignant melanoma","volume":"75","author":"Wr\u00f3blewska-\u0141uczka","year":"2023","journal-title":"Pharmacol Rep"},{"key":"2026050520321814400_bib29","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.3390\/ijms24087414","article-title":"Ursolic acid against prostate and urogenital cancers: a review of in vitro and in vivo studies","volume":"24","author":"Kornel","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026050520321814400_bib30","doi-asserted-by":"crossref","first-page":"67942","DOI":"10.18632\/oncotarget.18980","article-title":"AMPK activation-dependent autophagy compromises oleanolic acid-induced cytotoxicity in human bladder cancer cells","volume":"8","author":"Song","year":"2017","journal-title":"Oncotarget"},{"key":"2026050520321814400_bib31","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.bcp.2013.03.006","article-title":"Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies","volume":"85","author":"Shanmugam","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"2026050520321814400_bib32","volume-title":"ComMartinombinations: PC software and user\u2019s guide: A computer program for quantitation of synergism and antagonism in drug combinations, and the determination of IC50 and ED50 and LD50 values","author":"Chou","year":"2005"},{"key":"2026050520321814400_bib33","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.21873\/invivo.12155","article-title":"The effect of gemcitabine on cell cycle arrest and microRNA signatures in pancreatic cancer cells","volume":"34","author":"Namima","year":"2020","journal-title":"In Vivo"},{"key":"2026050520321814400_bib34","doi-asserted-by":"crossref","first-page":"774845","DOI":"10.3389\/fcell.2021.774845","article-title":"Cyclin E\/CDK2: DNA replication, replication stress and genomic instability","volume":"9","author":"Fagundes","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026050520321814400_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0076-6879(08)01606-6","article-title":"DNA damage response and apoptosis","volume":"446","author":"Plesca","year":"2008","journal-title":"Methods Enzymol"},{"key":"2026050520321814400_bib36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41419-023-06154-8","article-title":"Autophagy: regulator of cell death","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis"},{"key":"2026050520321814400_bib37","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1741-7007-9-38","article-title":"Concurrent detection of autolysosome formation and lysosomal degradation by flow cytometry in a high-content screen for inducers of autophagy","volume":"9","author":"Hundeshagen","year":"2011","journal-title":"BMC Biol"},{"key":"2026050520321814400_bib38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4161\/auto.6.2.11127","article-title":"Autophagy takes an alternative pathway","volume":"6","author":"Shimizu","year":"2010","journal-title":"Autophagy"},{"key":"2026050520321814400_bib39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5155\/eurjchem.12.2.192-196.2103","article-title":"Molecular docking analysis on the interaction between bovine serum albumin and three commercial fluoroquinolones: ciprofloxacin, enrofloxacin and pefloxacin","volume":"12","author":"Chaves","year":"2021","journal-title":"Eur J Chem"},{"key":"2026050520321814400_bib40","first-page":"4761","article-title":"Anticancer effect of ursolic acid via mitochondria-dependent pathways","volume":"17","author":"Feng","year":"2019","journal-title":"Oncol Lett"},{"key":"2026050520321814400_bib41","doi-asserted-by":"crossref","first-page":"e1900111","DOI":"10.1002\/cbdv.201900111","article-title":"Synthesis and antitumor evaluation in vitro of NO-donating ursolic acid-benzylidene derivatives","volume":"16","author":"Zhang","year":"2019","journal-title":"Chem Biodivers"},{"key":"2026050520321814400_bib42","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1007\/s13277-013-1604-3","article-title":"Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer","volume":"35","author":"Pinto-Leite","year":"2014","journal-title":"Tumour Biol"},{"key":"2026050520321814400_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)","volume":"12","author":"Klionsky","year":"2016","journal-title":"Autophagy"},{"key":"2026050520321814400_bib44","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2020.03.010","article-title":"Autophagy in cancer: recent advances and future directions","volume":"66","author":"Ishaq","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"2026050520321814400_bib45","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrm2239","article-title":"Self-eating and self-killing: crosstalk between autophagy and apoptosis","volume":"8","author":"Maiuri","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026050520321814400_bib46","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jnutbio.2012.04.004","article-title":"Ursolic acid induces cell death and modulates autophagy through JNK pathway in apoptosis-resistant colorectal cancer cells","volume":"24","author":"Xavier","year":"2013","journal-title":"J Nutr Biochem"},{"key":"2026050520321814400_bib47","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbamcr.2011.10.014","article-title":"Autophagy inhibition enhances ursolic acid-induced apoptosis in PC3 cells","volume":"1823","author":"Shin","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2026050520321814400_bib48","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1126\/science.1196371","article-title":"Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy","volume":"331","author":"Egan","year":"2011","journal-title":"Science"},{"key":"2026050520321814400_bib49","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3390\/cells8121627","article-title":"Structural biology and electron microscopy of the autophagy molecular machinery","volume":"8","author":"Lai","year":"2019","journal-title":"Cells"}],"container-title":["Molecular Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/doi\/10.1158\/1535-7163.MCT-23-0806\/3458894\/mct-23-0806.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/doi\/10.1158\/1535-7163.MCT-23-0806\/3464485\/mct-23-0806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/23\/10\/1389\/3502952\/mct-23-0806.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/23\/10\/1389\/3502952\/mct-23-0806.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:32:30Z","timestamp":1778027550000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/mct\/article\/23\/10\/1389\/748619\/Targeting-Chemoresistance-in-Advanced-Bladder"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":49,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5,30]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1535-7163.mct-23-0806","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/1535-7163.27142419","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27149640","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27149620","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27142413","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27149641","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27142422","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27149643","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27149632","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27142401","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27149635","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27142407","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27149637","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27142404","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27149614","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27142416","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27149617","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27149638","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27149629","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1535-7163.27142410","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/1535-7163.c.7474476","asserted-by":"object"}]},"ISSN":["1535-7163","1538-8514"],"issn-type":[{"value":"1535-7163","type":"print"},{"value":"1538-8514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]}}}